TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer

Transcode Therapeutics, Inc.

Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
Trial enrolls up to 45 colorectal cancer patients with ctDNA positivity after curative-intent therapy.
Phase 2a expected to start first half 2026; led by Dr. Paula Pohlmann of MD Anderson Cancer Center.
Decision based on positive Phase 1 safety data and durable anti-tumor effects.
TTX-MC138 targets metastatic disease; aims to intervene in minimal residual disease setting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.